EQRx, Inc. (EQRX)
|52 Week Range||1.58-6.05|
|1y Target Est||-|
|DCF Unlevered||EQRX DCF ->|
|DCF Levered||EQRX LDCF ->|
|Debt / Equity||4.76%||Neutral|
Upgrades & Downgrades
Latest EQRX news
EQRx, Inc. (EQRX) Q1 2023 Earnings Call Transcript
8 May 2023
Call Start: 16:30 January 1, 0000 4:57 PM ET EQRx, Inc. (NASDAQ:EQRX ) Q1 2023 Earnings Conference Call May 8, 2023 16:30 ET Company Participants Michelle Greenblatt - Head of Investor Relations Melan...
New Strong Buy Stocks for April 12th
12 April 2023
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 January 2023
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the...
Here's Why EQRx, Inc. (EQRX) is Poised for a Turnaround After Losing 23% in 4 Weeks
13 December 2022
The heavy selling pressure might have exhausted for EQRx, Inc. (EQRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...
EQRx, Inc. (EQRX) Q3 2022 Earnings Call Transcript
13 November 2022
EQRx, Inc. (NASDAQ:EQRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Neil Swami - Head, Investor Relations Melanie Nallicheri - President and Chief Executive Of...
A Biotech Steps Back From Bold Plan to Drop Drug Prices. A Stunning Selloff.
10 November 2022
Share of EQRx plunged 28.6% after the drugmaker said it would sell two cancer drugs at market prices, instead of the cut-rate prices it had promised.
Why EQRx Shares Dropped 28.62% on Thursday
10 November 2022
The company suspended trials for one of its lead therapies.
Why Earnings Season Could Be Great for EQRx (EQRX)
9 November 2022
EQRx (EQRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
28 October 2022
CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substanti...
EQRx, Inc. (EQRX) CEO Melanie Nallicheri on Q2 2022 Results - Earnings Call Transcript
13 August 2022
EQRx, Inc. (NASDAQ:EQRX ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Neil Swami - Head, IR Melanie Nallicheri - President and CEO Jami Rubin - CFO Eric Hedrick - ...
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >